Benzinga | Dec 1, 2021 08:00AM EST

EXCLUSIVE: Applied UV Says Its Exclusive Distribution Partner In Thailand Will Be Installing Co's Airocide Units At Armed Forces Research Institute Of Medical Sciences In Bangkok, Thailand

Mount Vernon, NY // December 1, 2021 -- Applied UV, Inc. (NasdaqCM: AUVI)

("Applied UV" or the "Company"), a pathogen elimination technology

company that applies the power of narrow-range ultraviolet light ("UVC") for

surface areas and catalytic bioconversion technology for air purification to

destroy pathogens safely, thoroughly, and automatically, announced that its

exclusive distribution partner in Thailand will be installing Airocide(r) units at

the Armed Forces Research Institute of Medical Sciences ("AFRIMS"),

Bangkok, Thailand, to help create safer and cleaner environments for

visitors and staff. AFRIMS is a biomedical research facility of the U.S. Army's

Walter Reed Army Institute of Research ("WRAIR"). AFRIMS, with a mission

that has resulted in ground-breaking research in military medicine across

nations in Southeast Asia and the Indian Subcontinent, has primarily focused

on diseases related to infectious pathogens.

AFRIMS has a dual Royal Thai Army and US Army Command with the

American Component being a special foreign activity of the WRAIR in

Washington, DC. Since 1893, the WRAIR has been a leader in solving

significant threats to Soldier readiness and lethality such as disease

and battle injury. WRAIR's broad research capabilities at its Washington,

D.C., area and expeditionary laboratories function in concert to afford

Soldiers the best medical protection and support possible before, during, and

after deployment by addressing both longstanding and emerging threats.

Though WRAIR's research is focused on Soldier health, its products have

important civilian applications, saving countless lives around the world.

With the ongoing fight against COVID-19 and the recent global emergence of

the new Omicron strain, AFRIMS is installing Airocide(r) systems to control

airborne diseases and protect critical areas within the facility. The

installation of the Airocide GCS series units at the research facility

demonstrates the commitment of Thailand's medical community to seek out

and provide the best in air purification and sanitizing technology by which to

protect their employees.

Armed with one of the only known, FDA Listed Class II Medical Devices that

has been clinically proven to kill COVID 19, Applied UV continues to enhance

its distributor relationships throughout Southeast Asia and around the world

to meet the demand for its air and surface infection control products. The

installation at this leading military research facility coupled with other global

installations (JetBlue Park, Boston Red Sox, US Army Aberdeen Proving

Grounds, Bangkok Metropolitan Administration Lat Krabang Hospital, Palace

of Versailles) further demonstrates the efficacy and safety of the patented

Airocide air purification platform by having these institutions trust the

protection of their staffs, consumers and facilities with our product.

"The installation of our Airocide(r) units at such a prestigious biomedical

facility represents another significant milestone in our strategy to

significantly grow our international commercial distribution capabilities and

enter new markets," said Max Munn, Founder and President of Applied UV.

"Our Thailand distributor, Sithiporn Associates, is one of the leading scientific

equipment distributors in Thailand and ASEAN region and have been

excellent partners to commercialize our innovative and clinically proven

portfolio of pathogen eliminating technology. Hospitals and research facilities

are increasingly recognizing the benefits of installing Airocide(r) systems in

communal spaces to interrupt the transmission of airborne infectious agents

and destroy those microbes rapidly while keeping the occupants safe from

any harmful byproducts."

Airocide(r) utilizes NASA optimized photocatalytic oxidation ("PCO")

technology wherein air and any contaminants are drawn from the room into

the Airocide(r) unit and channeled into the reaction chamber. UVC activates

the proprietary photocatalyst embedded in the reaction chamber, beginning

the photocatalytic process. In the reaction chamber, hydroxyl radicals and

super-oxide ions are generated and oxidize every organic molecule that

comes in contact. The reaction bed is designed to allow the surface-bound

radicals nearly three hundred and sixty degrees of exposure for maximum

likelihood of collisions with pathogens and other organic material. Millions of

hydroxyl radicals converge, combining with the carbon atoms in pathogens

(airborne bacteria, mold, fungi, mycotoxins, viruses, allergens) and VOCs,

converting the organic material into a harmless vapor and clean, clear air.

Airocide System

The Airocide(r) System, originally developed for NASA with assistance from

the University of Wisconsin at Madison, is an airborne pathogen killing

technology that uses a patented combination of UVC and a proprietary,

titanium dioxide based photocatalyst. Listed as an FDA Class II Medical

device, the Airocide(r) technology is clinically proven and field tested to

kill/remove/eliminate airborne pathogenic and non-pathogenic

microorganisms, allergens, odors and harmful VOCs in a variety of

applications and industries including healthcare, hospitality, grocery chains,

wineries, commercial real estate, schools, dental offices and homes.

Airocide(r) air purifiers are available at www.airocide.com

About Applied UV

Applied UV is focused on the development and acquisition of technology that

address infection control in the healthcare, hospitality, commercial and

municipal markets. The Company has two wholly owned subsidiaries -

SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works").

SteriLumen's connected platform for Data Driven Disinfection(tm) applies the

power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and

automatically, addressing the challenge of healthcare-acquired infections

("HAIs"). Targeted for use in facilities that have high customer turnover such

as hospitals, hotels, commercial facilities, and other public spaces, the

Company's Lumicide(tm) platform uses UVC LEDs in several patented designs

for infection control in and around high-traffic areas, including sinks and

restrooms, killing bacteria, viruses, and other pathogens residing on hard

surfaces within devices' proximity. The Company's patented in-drain

disinfection device, Lumicide Drain, is the only product on the market that

addresses this critical pathogen intensive location. SteriLumen's Airocide(r)

products for air purification, developed for NASA and FDA Cleared as class II

medical devices, utilize a proprietary photo-catalytic bioconversion

technology that draws air into a reaction chamber that converts damaging

molds, microorganisms, dangerous pathogens, destructive VOCs and

biological gasses into harmless water vapor without producing ozone or

other harmful byproducts. Airocide(r) applications include healthcare,

hospitality, grocery chains, wine making facilities, commercial real estate,

schools, dental offices, and homes.

For more information about Applied UV, Inc., and its subsidiaries, please visit

the following websites: https://www.applieduvinc.com/;

https://sterilumen.com/; and, https://munnworks.com/.

Forward-Looking Statements

The information contained herein may contain "forwardlooking statements."

Forwardlooking statements reflect the current view about future events.

When used in this press release, the words "anticipate," "believe,"

"estimate," "expect," "future," "intend," "plan," or the negative of these

terms and similar expressions, as they relate to us or our management,

identify forwardlooking statements. Such statements include, but are not

limited to, statements contained in this press release relating to the view of

management of Applied UV concerning its business strategy, future

operating results and liquidity and capital resources outlook. Forwardlooking

statements are based on the Company's current expectations and

assumptions regarding its business, the economy and other future

conditions. Because forward--looking statements relate to the future, they

are subject to inherent uncertainties, risks and changes in circumstances

that are difficult to predict. The Company's actual results may differ

materially from those contemplated by the forwardlooking statements. They

are neither statements of historical fact nor guarantees of assurance of

future performance. We caution you therefore against relying on any of

these forwardlooking statements. Factors or events that could cause the

Company's actual results to differ may emerge from time to time, and it is

not possible for the Company to predict all of them. The Company cannot

guarantee future results, levels of activity, performance, or achievements.

Except as required by applicable law, including the securities laws of the

United States, the Company does not intend to update any of the forward

looking statements to conform these statements to actual results.